L. Guyader-peyrou and S. , Cancer incidence in France over the 1980-2012 period: Hematological malignancies, Rev. Epidemiol. Sante Publique, vol.64, pp.103-112, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01511580

C. Bonnet, Prise en charge du lymphome B diffus à grandes cellules en 2012

S. H. Swerdlow, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, pp.2375-2390, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

J. Bruneau, Classification OMS 2016 des hémopathies lymphoïdes matures, Feuill. Biol, p.11, 2017.

M. A. Shipp, A Predictive Model for Aggressive Non-Hodgkin's Lymphoma, New England Journal of Medicine, vol.329, issue.14, pp.987-994, 1993.

C. H. Moskowitz, The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma, Bone Marrow Transplant, vol.23, pp.561-567, 1999.

P. A. Hamlin, Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma, Blood, vol.102, pp.1989-1996, 2003.

M. Ziepert, Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20 + B-Cell Lymphoma in the Rituximab Era, J. Clin. Oncol, vol.28, pp.2373-2380, 2010.

Z. Zhou, An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era, Blood, vol.123, pp.837-842, 2014.

P. N. Meyer, Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab, J. Clin. Oncol, vol.29, pp.200-207, 2011.

G. Held and M. Pfreundschuh, Germinal center or nongerminal center DLBCL?: Hematology, Nat. Rev. Clin. Oncol, vol.6, pp.188-190, 2009.

P. Sesques and N. A. Johnson, Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements, Blood, vol.129, pp.280-288, 2017.

N. A. Johnson, Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.30, pp.3452-3459, 2012.

S. Hu, MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program, Blood, vol.121, pp.4021-4031, 2013.

H. Horn, MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma, Blood, vol.121, issue.12, pp.2253-2263, 2013.

S. A. Rosenberg, Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas, Cancer Treat. Rep, vol.61, pp.1023-1027, 1977.

T. A. Lister, Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.7, pp.1630-1636, 1989.

K. Van-besien, Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma, Blood, vol.91, issue.4, pp.1178-1184, 1998.

B. Coiffier, Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.9, pp.211-219, 1991.

M. M. Oken, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am. J. Clin. Oncol, vol.5, p.649, 1982.

F. Swan, A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.7, pp.1518-1527, 1989.

S. Dalia, Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era, Ann. Hematol, vol.93, pp.1305-1312, 2014.

, Référentiel 2009 de la Société Française d'hématologie

P. Feugier, Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.23, pp.4117-4126, 2005.

B. Coiffier, State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma, Journal of Clinical Oncology, vol.23, issue.26, pp.6387-6393, 2005.

S. J. Horning, Chemotherapy With or Without Radiotherapy in Limited-Stage Diffuse Aggressive Non-Hodgkin's Lymphoma: Eastern Cooperative Oncology Group Study 1484, J. Clin. Oncol, vol.22, pp.3032-3038, 2004.

T. Philip, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma, N. Engl. J. Med, vol.333, pp.1540-1545, 1995.

C. Gisselbrecht, Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era, J. Clin. Oncol, vol.28, pp.4184-4190, 2010.

W. H. Sweet, The Uses of Nuclear Disintegration in the Diagnosis and Treatment of Brain Tumor, New England Journal of Medicine, vol.245, issue.23, pp.875-878, 1951.

M. Ter-pogossian, A Positron-Emission Transaxial Tomograph for Nuclear Imaging (PETT), Radiology, vol.114, issue.1, pp.89-98, 1975.

T. Beyer, A combined PET/CT scanner for clinical oncology

, J. Nucl. Med. Off. Publ. Soc. Nucl. Med, vol.41, pp.1369-1379, 2000.

M. E. Juweid and B. D. Cheson, Role of Positron Emission Tomography in Lymphoma, J. Clin. Oncol, vol.23, pp.4577-4580, 2005.

M. E. Juweid, Response Assessment of Aggressive Non-Hodgkin's Lymphoma by Integrated International Workshop Criteria and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography, J. Clin. Oncol, vol.23, pp.4652-4661, 2005.

, Nuclide Safety Data Sheet Fluorine, vol.18

S. F. Barrington and N. G. Mikhaeel, When should FDG-PET be used in the modern management of lymphoma?, Br. J. Haematol, vol.164, pp.315-328, 2014.

M. Weiler-sagie, 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients, J. Nucl. Med, vol.51, pp.25-30, 2010.

R. Watanabe, SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma, Leuk. Lymphoma, vol.51, pp.279-283, 2010.

S. F. Barrington, Role of Imaging in the Staging and Response Assessment of Lymphoma, Consensus of the International Conference on Malignant Lymphomas Imaging Working Group, vol.32, pp.3048-3058, 2014.

C. Lin, Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis, J. Nucl. Med, vol.48, pp.1626-1632, 2007.

D. Chihara, High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma, Int. J. Hematol, vol.93, pp.502-508, 2011.

R. Casasnovas, SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma, Blood, vol.118, pp.37-43, 2011.

E. Itti, Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy, J. Nucl. Med, vol.50, pp.527-533, 2009.

E. Itti, An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ?SUVmax, Eur. J. Nucl. Med. Mol. Imaging, vol.40, pp.1312-1320, 2013.

M. Meignan, Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma, Leuk. Lymphoma, vol.53, pp.1876-1881, 2011.

U. Dührsen, Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial, J. Clin. Oncol, vol.36, pp.2024-2034, 2018.

S. M. Larson, Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis, Clin. Positron Imaging Off. J. Inst. Clin. PET, vol.2, pp.159-171, 1999.

H. Ilyas, Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma, Eur. J. Nucl. Med. Mol. Imaging, vol.45, pp.1142-1154, 2018.

M. Hatt, A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET, IEEE Trans. Med. Imaging, vol.28, pp.881-893, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00372910

R. Boellaard, FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0, Eur. J. Nucl. Med. Mol. Imaging, vol.42, pp.328-354, 2015.

P. Raanani, Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?, Ann. Oncol, vol.17, pp.117-122, 2006.

T. C. El-galaly, Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuselarge B-cell lymphoma, Am. J. Hematol, vol.90, pp.1041-1046, 2015.

T. C. El-galaly, Female patients with DLBCL and involvement of the reproductive organs have poor outcomes and markedly increased risk of CNS relapse with R-CHOP(-like) therapy, Hematological Oncology, vol.33, pp.209-210, 2015.

L. Berthet, In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy, J. Nucl. Med. Off. Publ. Soc. Nucl. Med, vol.54, pp.1244-1250, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00927556

A. B. Khan, PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement, Blood, vol.122, pp.61-67, 2013.

C. S. Ujjani, 18) F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma, Br. J. Haematol, vol.174, pp.410-416, 2016.

M. Alzahrani, The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study, Ann. Oncol, vol.27, pp.1095-1099, 2016.

N. Keromnes, FDG PET/CT for Initial Staging of Diffuse Large B-Cell Lymphoma: Is Diffuse Bone Marrow Uptake a Reflection of Disease Involvement?, J. Bone Res, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01296912

J. J. Cerci, Combined PET and Biopsy Evidence of Marrow Involvement Improves Prognostic Prediction in Diffuse Large B-Cell Lymphoma, J. Nucl. Med, vol.55, pp.1591-1597, 2014.

J. Campbell, The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement, Eur. J. Haematol, vol.76, pp.473-480, 2006.

L. H. Sehn, Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP, J. Clin. Oncol, vol.29, pp.1452-1457, 2011.

H. Adams, FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis, European Journal of Nuclear Medicine and Molecular Imaging, vol.41, pp.565-574, 2013.

D. Sfmn and . Au, Recommandations de Bonne Pratique Clinique pour l'utilisation de la TEP

M. Pfreundschuh, Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study, Lancet Oncol, vol.9, pp.435-444, 2008.

S. S. Saboo, Spleen in haematological malignancies: spectrum of imaging findings, Br. J. Radiol, vol.85, pp.81-92, 2012.

G. Larcos and M. N. Maisey, FDG-PET screening for cerebral metastases in patients with suspected malignancy, Nucl. Med. Commun, vol.17, p.197, 1996.

M. E. Juweid, Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma, J. Clin. Oncol, vol.25, pp.571-578, 2007.

K. Manohar, Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma, Leuk. Lymphoma, vol.54, pp.714-719, 2013.

R. L. Elstrom, Response assessment in lymphoma: time to lower the bar?, Leuk. Lymphoma, vol.54, pp.673-674, 2013.

M. Meignan, E. Itti, A. Gallamini, and C. Haioun, Interim 18 F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation -where do we stand?, Leuk. Lymphoma, vol.50, pp.1753-1756, 2009.

A. Gallamini, The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale, Haematologica, vol.99, pp.1107-1113, 2014.

K. Hanaoka, Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin?s lymphoma, Nucl. Med. Commun, vol.32, pp.678-683, 2011.

S. F. Barrington, Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma, Eur. J. Nucl. Med. Mol. Imaging, vol.37, pp.1824-1833, 2010.

J. S. Newman, I. R. Francis, M. S. Kaminski, and R. L. Wahl, Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT, Radiology, vol.190, pp.111-116, 1994.

T. Terasawa, T. Nihashi, T. Hotta, and H. Nagai, 18F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review, J. Nucl. Med, vol.49, pp.13-21, 2008.

H. Hagberg and C. Gisselbrecht, Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study, Ann. Oncol, vol.17, pp.31-32, 2006.

K. Spaepen, Early restaging positron emission tomography with

, F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.13, pp.1356-1363, 2002.

N. G. Mikhaeel, M. Hutchings, P. A. Fields, M. J. O'doherty, and A. R. Timothy, FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in highgrade non-Hodgkin lymphoma, Ann. Oncol, vol.16, pp.1514-1523, 2005.

C. Haioun, 18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome, Blood, vol.106, pp.1376-1381, 2005.

A. F. Cashen, 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation, J. Nucl. Med, vol.52, pp.386-392, 2011.

C. Yoo, Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP, Ann. Hematol, vol.90, pp.797-802, 2011.

P. L. Zinzani, Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma, Cancer, vol.117, pp.1010-1018, 2011.

V. Safar, Interim [ 18 F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab, J. Clin. Oncol, vol.30, pp.184-190, 2012.

D. Yang, Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era, Ann. Hematol, vol.92, pp.471-479, 2013.

C. Mamot, Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07), J. Clin. Oncol, vol.33, pp.2523-2529, 2015.

J. Kim, Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores, Leuk. Lymphoma, vol.59, pp.340-347, 2018.

I. Avivi, Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era, Am. J. Hematol, vol.88, pp.400-405, 2013.

A. Gallamini and C. Zwarthoed, Interim FDG-PET Imaging in Lymphoma, Semin. Nucl. Med, vol.48, pp.17-27, 2018.

L. F. Oñate-ocaña, Metabolic tumor volume changes assessed by interval 18-fluorodeoxyglucose positron emission tomography-computed tomography for the prediction of complete response and survival in patients with diffuse large B-cell lymphoma, Oncol. Lett, vol.16, pp.1411-1418, 2018.

L. Gouill, S. Casasnovas, and R. , Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?, Blood, vol.129, pp.3059-3070, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01556383

B. D. Cheson and . Pet/ct-in-lymphoma, Current Overview and Future Directions, Semin. Nucl. Med, vol.48, pp.76-81, 2018.

U. Cremerius, Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma, Bone Marrow Transplant, vol.30, pp.103-111, 2002.

K. Spaepen, Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation, Blood, vol.102, pp.53-59, 2003.

J. Filmont, The impact of pre-and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation, Cancer, vol.110, pp.1361-1369, 2007.

B. W. Schot, Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma, Blood, vol.109, pp.486-491, 2007.

E. Derenzini, Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma, Cancer, vol.113, pp.2496-2503, 2008.

M. Dickinson, Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy: Pre-Transplant PET for Relapsed Lymphoma, Br. J. Haematol, vol.150, pp.39-45, 2010.

V. Roland, Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients, Bone Marrow Transplant, vol.46, pp.393-399, 2011.

B. D. Cheson, Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas, J. Clin. Oncol, vol.17, pp.1244-1244, 1999.

S. Akhtar, Pre-transplant 18 F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT, Bone Marrow Transplant, vol.48, pp.551-556, 2013.

P. Armand, Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era, Br. J. Haematol, vol.160, pp.608-617, 2013.

C. S. Sauter, Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma, Blood, vol.125, pp.2579-2581, 2015.

A. Winter, Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation, Leuk. Lymphoma, vol.59, pp.1195-1201, 2018.

H. R. Jang, The median number of chemotherapy regimens prescribed before transplantation was two (range 1-3). Most patients had disease refractory to first-line therapy (45/62, 73%); 17/62 patients proceeded to ASCT because of relapse. The 4year PFS and OS were 83% (95% CI 73-93%) and 88% (95% CI 80-97%), respectively. The causes of death were related to disease progression in seven cases. Two patients died of solid cancers (lung, kidney) and one because of an accident. After salvage chemotherapy, 31/62 patients (50%) exhibited positive pre-transplant PET/CT, defined as a Deauville score >3; 21 patients had Deauville scores of 4, and 9 had scores of 5. A positive PET/CT result was not significantly associated with either PFS or OS, Maximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma, vol.50, p.97, 2015.

S. Akhtar, A. S. Al-sugair, M. Abouzied, Y. Alkadhi, M. Dingle et al., , pp.Pre-transplant, 2013.

. F-fluorodeoxyglucose, positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT, Bone Marrow Transplant, vol.48, pp.551-556

P. Armand, S. Welch, H. T. Kim, A. S. Lacasce, E. D. Jacobsen et al., Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era, Br J Haematol, vol.160, pp.608-617, 2013.

I. Avivi, A. Zilberlicht, E. J. Dann, R. Leiba, T. Faibish et al., Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era, Am J Hematol, vol.88, pp.400-405, 2013.

S. F. Barrington, N. G. Mikhaeel, L. Kostakoglu, M. Meignan, M. Hutchings et al., Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group, vol.32, pp.3048-3058, 2014.

R. Boellaard, M. J. O'doherty, W. A. Weber, F. M. Mottaghy, M. N. Lonsdale et al., EANM procedure guidelines for tumour PET imaging: version 1.0, Eur J Nucl Med Mol Imaging, vol.37, pp.181-200, 2010.

B. D. Cheson, R. I. Fisher, S. F. Barrington, F. Cavalli, L. H. Schwartz et al., Nordic Lymphoma Study, G., Southwest Oncology, G. & United Kingdom National Cancer Research, I. (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, vol.32, pp.3059-3068

A. S. Cottereau, H. Lanic, S. Mareschal, M. Meignan, P. Vera et al., Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma, Clin Cancer Res, vol.22, pp.3801-3809, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01644008

U. Cremerius, U. Fabry, J. E. Wildberger, M. Zimny, P. Reinartz et al., Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma, Bone Marrow Transplant, vol.30, pp.103-111, 2002.

E. Derenzini, G. Musuraca, S. Fanti, V. Stefoni, M. Tani et al., Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma, Cancer, vol.113, pp.2496-2503, 2008.

M. Dickinson, R. Hoyt, A. W. Roberts, A. Grigg, J. F. Seymour et al., Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy, Br J Haematol, vol.150, pp.39-45, 2010.

U. Duhrsen, S. Muller, B. Hertenstein, H. Thomssen, J. Kotzerke et al., Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial, vol.36, pp.2024-2034, 2018.

C. Gisselbrecht, B. Glass, N. Mounier, D. Singh-gill, D. C. Linch et al., Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, J Clin Oncol, vol.28, pp.4184-4190, 2010.

B. Guo, X. Tan, Q. Ke, and H. Cen, Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis, PLoS One, vol.14, p.210224, 2019.

M. Hertzberg, M. K. Gandhi, J. Trotman, B. Butcher, J. Taper et al., Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim, Haematologica, vol.102, pp.356-363, 2017.

C. Mamot, D. Klingbiel, F. Hitz, C. Renner, T. Pabst et al., Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07), J Clin Oncol, vol.33, pp.2523-2529, 2015.

N. G. Mikhaeel, D. Smith, J. T. Dunn, M. Phillips, H. Moller et al., Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL, Eur J Nucl Med Mol Imaging, vol.43, pp.1209-1219, 2016.

S. S. Neelapu, F. L. Locke, N. L. Bartlett, L. J. Lekakis, D. B. Miklos et al., Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med, vol.377, pp.2531-2544, 2017.

T. Philip, C. Guglielmi, A. Hagenbeek, R. Somers, H. Van-der-lelie et al., Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma, N Engl J Med, vol.333, pp.1540-1545, 1995.

W. Qiao, J. Zhao, Y. Xing, C. Wang, and T. Wang, )F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant, Leuk Lymphoma, vol.55, issue.1, pp.276-282, 2014.

C. S. Sauter, M. J. Matasar, J. Meikle, H. Schoder, G. A. Ulaner et al., Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma, Blood, vol.125, pp.2579-2581, 2015.

K. Spaepen, S. Stroobants, P. Dupont, P. Vandenberghe, J. Maertens et al., Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation, Blood, vol.102, pp.53-59, 2003.

B. Tessoulin, P. Thomare, E. Delande, J. Moynard, T. Gastinne et al., Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas, Ann Hematol, vol.96, pp.943-950, 2017.

A. Winter, L. Rybicki, S. N. Shah, D. Jagadeesh, A. T. Gerds et al., Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation, Leuk Lymphoma, vol.59, pp.1195-1201, 2018.

P. Ziai, M. R. Hayeri, A. Salei, A. Salavati, S. Houshmand et al., Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology, Radiographics, vol.36, pp.481-496, 2016.